Zimmer Biomet Holdings Inc (ZBH)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Zimmer Biomet Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 93.90 $ — 51% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 5.9% failed
- More than 10% revenue growth is expected for the coming year 3.4% failed
- Share count grows by less than 3% a year -1.9% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 25.1% failed
- Gross margin at 40% or higher and without meaningful erosion 61.6% failed
- Goodwill from acquisitions does not grow faster than revenue 43.1% passed
- Net debt below twice EBITDA 3.1 x EBITDA failed
- Operating cash flow covers the profits of the last three years 2,145 m passed
- Return on capital at 15% or higher, or up versus two years ago 6.6% failed
- Insiders hold at least 10% or are net buyers 0.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 5.8% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 29
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8.47 | 8.29 – 8.53 | 8,545 | 3.3% | 26 |
| 12/31/2027 | 9.00 | 8.44 – 9.77 | 8,845 | 6.3% | 27 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 2.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.20 | -40.40 | 2,023 | 4.30 | 11.80 | 506 | 421 |
| 2025: Q1 | 0.91 | 9.00 | 1,909 | 1.10 | 9.50 | 383 | 336 |
| 2025: Q2 | 0.77 | -34.50 | 2,077 | 7.00 | 7.40 | 378 | 298 |
| 2025: Q3 | 1.16 | -5.30 | 2,001 | 9.70 | 11.50 | 419 | 546 |
| 2025: Q4 | 0.70 | -41.20 | 2,244 | 10.90 | 6.20 | 517 | 669 |
| 2026: Q1 | 1.22 | 33.40 | 2,087 | 9.30 | 11.40 | 359 | 323 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 7,668 | 821 | 306 | 1.51 | 1,632 | 9,669 | 26,684 |
| 2017 | 7,803 | 799 | 1,814 | 8.90 | 1,582 | 11,736 | 26,014 |
| 2018 | 7,933 | 34 | -379 | -1.86 | 1,747 | 11,271 | 24,127 |
| 2019 | 7,982 | 1,138 | 1,132 | 5.47 | 1,586 | 12,388 | 24,639 |
| 2020 | 6,128 | 83 | -139 | -0.67 | 1,205 | 12,194 | 24,418 |
| 2021 | 6,827 | 860 | 402 | 1.91 | 1,499 | 12,661 | 23,456 |
| 2022 | 6,940 | 696 | 231 | 1.10 | 1,285 | 12,020 | 21,066 |
| 2023 | 7,394 | 1,278 | 1,024 | 4.88 | 1,582 | 12,481 | 21,497 |
| 2024 | 7,679 | 1,286 | 904 | 4.43 | 1,499 | 12,468 | 21,365 |
| 2025 | 8,232 | 1,362 | 705 | 3.55 | 1,697 | 12,698 | 23,092 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Zimmer Biomet Holdings, Inc. ist mit ihren Tochtergesellschaften ein weltweit tätiges Medizintechnikunternehmen.
| Employees | 17,000 |
|---|---|
| Headquarters | Warsaw, IN |
| Address | 345 East Main Street, 46580 Warsaw, United States |
| Phone | 574 373 3333 |
| Website | zimmerbiomet.com |
| IPO Date | 25. Jul 2001 |
| ISIN | US98956P1021 |
| Stock Split | 103:100 on 03/01/2022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ivan Tornos | President, CEO & Chairman of the Board | 1975 |
| Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 1970 |
| JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | 1982 |
| Kevin R. Thornal | Group President of Global Businesses & Americas | 1974 |
| Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 1975 |
| Shaun Braun | Senior VP & Chief Information and Technology Officer | – |
| Jonathan M. Vigdorchik M.D. | Chief Science, Technology & Medical Affairs Officer | – |
| David M. DeMartino | Senior Vice President of Investor Relations | – |
| Chad F. Phipps J.D. | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 1972 |
| Angela Main | Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.